ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 198 filers reported holding ROYALTY PHARMA PLC in Q4 2020. The put-call ratio across all filers is 2.07 and the average weighting 1.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,035,556 | +0.9% | 185,540 | +14.2% | 0.01% | 0.0% |
| Q2 2023 | $4,993,098 | +16.2% | 162,430 | +36.1% | 0.01% | 0.0% |
| Q1 2023 | $4,298,811 | +1.8% | 119,312 | +11.3% | 0.01% | -16.7% |
| Q4 2022 | $4,223,050 | +6.8% | 107,184 | +8.9% | 0.01% | -7.7% |
| Q3 2022 | $3,953,000 | +4.1% | 98,384 | +9.0% | 0.01% | -23.5% |
| Q2 2022 | $3,796,000 | +19.4% | 90,284 | +10.7% | 0.02% | +30.8% |
| Q1 2022 | $3,179,000 | -2.6% | 81,584 | -1.7% | 0.01% | 0.0% |
| Q4 2021 | $3,263,000 | +104.1% | 83,036 | +87.7% | 0.01% | +62.5% |
| Q3 2021 | $1,599,000 | +7.4% | 44,236 | +21.7% | 0.01% | 0.0% |
| Q2 2021 | $1,489,000 | -6.8% | 36,336 | -0.8% | 0.01% | -20.0% |
| Q1 2021 | $1,597,000 | +47.3% | 36,613 | +69.0% | 0.01% | +25.0% |
| Q4 2020 | $1,084,000 | – | 21,664 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $294,957,000 | 88.74% |
| Vantage Consulting Group Inc | 8,705,551 | $379,735,000 | 76.23% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $116,930,000 | 72.07% |
| HARVARD MANAGEMENT CO INC | 10,714,284 | $467,357,000 | 26.11% |
| ROBERT WOOD JOHNSON FOUNDATION | 970,151 | $4,231,798,000 | 21.59% |
| Brown University | 381,759 | $16,652,000 | 11.44% |
| Overbrook Management Corp | 771,155 | $33,638,000 | 7.48% |
| SpiderRock Advisors, LLC | 778,800 | $34,236,000 | 4.79% |
| Renaissance Capital LLC | 452,948 | $19,758,000 | 2.93% |
| Lagoda Investment Management, L.P. | 104,835 | $4,573,000 | 2.28% |